Tyra Biosciences, Inc.
NMS: TYRALive Quote
📈 ZcoreAI Score
Our AI model analyzes Tyra Biosciences, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get TYRA Z-Score →About Tyra Biosciences, Inc.
Healthcare
Biotechnology
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is FGFR3, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in clinical trial for intrahepatic cholangiocarcinoma; and TYRA-430 for the treatment of hepatocellular carcinoma. Tyra Biosciences, Inc. was incorporated in 2018 and is headquartered in Carlsbad, California.
📊 Fundamental Analysis
Tyra Biosciences, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -39.8%, which indicates that capital utilization is currently under pressure.
At a current price of $35.26, TYRA currently trades near the top of its 52-week range (84%) (Range: $7.80 - $40.65).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Debt/Equity
Elevated
🔴
Return on Equity
Weak
⚠️
Beta (Risk)
Moderate Volatility
Key Financials
Market Cap
$1.90B
Trailing P/E
--
Forward P/E
-13.77
Beta (5Y)
0.96
52W High
$40.65
52W Low
$7.80
Avg Volume
997K
Day High
Day Low